Lumos Pharma

Lumos Pharma is a clinical-stage biopharmaceutical company with a mission to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. The company is committed to a strategy grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients. Their clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment. As a key component of its mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. The company leverages its experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. The last investment of $34.00M Series B occurred on 06 April 2016 and involved investors such as Santé Ventures, Roche Venture Fund, Deerfield, Clarus Ventures. With a commitment to patients, their families, and the broader community impacted by rare diseases, Lumos Pharma aims to be a leading provider of innovative medications that address a multitude of rare diseases.